Pre-market · Regular session opens 9:30 AM ET
Last update: Sep 11, 2026, 6:10 PM ET
Merck & Co., Inc.
$143.94 0.54% today
Pre-market

Why Merck & Co., Inc. (MRK) stock moved

Updated Sep 14, 2026

Merck & Co., Inc. (MRK) shares fell 0.5% to $143.94 as of September 14, 2026, a slight decline from the prior close of $144.71. BestStocks flagged the session as a major change for MRK. Below, we break down what changed for MRK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

MRK fell 0.5% to $143.94

MRK fell 0.5% in its latest session, moving from $144.71 to $143.94.

Sector-Wide MoveWeak confidence
Rel. volume
0.8×
Below Avg
Vs peers
Top 4 of 7 peers
In Line With Peers
Market cap
$355.5B
New York Stock Exchange
Analyst target
$158
+9.9% vs price
Price chart
Aug 14 – Sep 14
VVVV$135$146$157Aug 14Aug 21Aug 28Sep 4Sep 14
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Merck & Co., Inc. investors

For Merck & Co., Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Merck surged +12.35% to $151.87 after announcing positive Phase 3 trial results for its personalized mRNA melanoma vaccine (INTerpath-001) developed with Moderna, per web sources; Merck & Co., Inc. (MRK) moved +3.25% from $123.61 to $127.63 on 2026-07-16. Weighing against that: Negative session, down 0.5%; Merck & Co., Inc. (MRK) moved -2.62% from $124.03 to $120.78 on 2026-07-14. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in MRK's fundamentals. Wall Street's consensus price target sits at $158.12, implying +9.9% upside from $143.94. Over the past 90 days analysts logged 2 upgrades and 1 downgrade. BestStocks rates the overall signal quality weak (30/100). With earnings roughly 45 days out, the next report is the most likely near-term test of the move.

MRK price reaction

MRK last traded at $143.94, down $0.78 (-0.54%) from the previous close of $144.71. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -0.3% over the same stretch, leaving MRK essentially in line with peers. Over the past month the stock has ranged between $135.17 and $156.45, and it currently sits about 41% of the way up that band.

Bullish and bearish analyst opinions on Merck & Co., Inc. (MRK)

The consensus analyst price target on Merck & Co., Inc. (MRK) is $158.12, 9.9% above the recent $143.94. Over the past 90 days analysts logged 2 upgrades, 21 maintains, and 1 downgrade. Here is how the bullish and bearish cases on MRK line up.

The bullish case

  • Wall Street's consensus price target of $158.12 implies +9.9% upside from $143.94.
  • The Street's most bullish target is $180.00 (+25.1%).
  • 2 analyst upgrades in the past 90 days, most recently Morgan Stanley to Overweight (2026-08-20).
  • Merck surged +12.35% to $151.87 after announcing positive Phase 3 trial results for its personalized mRNA melanoma vaccine (INTerpath-001) developed with Moderna, per web sources.
  • Merck & Co., Inc. (MRK) moved +3.25% from $123.61 to $127.63 on 2026-07-16.

The bearish case

  • The most bearish analyst target is $105.00 (-27.1%).
  • 1 analyst downgrade in the past 90 days, most recently RBC Capital to Sector Perform (2026-08-20).
  • Negative session, down 0.5%.
  • Merck & Co., Inc. (MRK) moved -2.62% from $124.03 to $120.78 on 2026-07-14.
  • MRK fell 2.68% to $125.06 on below-average volume (0.42x expected for this time of day).
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Sep 14, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $158+9.9%
2 upgrades= 21 maintains1 downgrades
HSBC maintained Buy · 2026-09-10
SEC filings watch
10-Q2026-08-07
Quarterly financial results
medium
8-K2026-08-04
Material event — review for impact
high
8-K2026-05-28
Material event — review for impact
high
8-K2026-05-22
Material event — review for impact
high
Peer context
MRK-0.5%
LLY-0.7%
UNH-2.4%
JNJ-0.3%
PFE+0.3%
ABBV+0.8%

Previous notable changes for MRK

Valuation2026-08-21+2.4%via CNBC
Merck gained 2.18% to $152.50 following positive Phase 3 clinical trial results for its personalized mRNA cancer vaccine developed with Moderna, combined with Keytruda, which met primary efficacy goals for recurrence-free survival in high-risk patients. Goldman Sachs and other major institutions subsequently raised price targets on the stock, driving investor enthusiasm in oncology-focused equities.
Valuation2026-08-20-2.1%via fortune.com
Merck fell 1.34% to $150.18, with elevated volume (2.61x normal for this time of day at 3.76M shares) cited by Google's AI Overview as linked to reporting on the company—likely related to vaccine developments or pipeline news flagged by Fortune, MarketWatch, and Yahoo Finance on 2026-08-20.
Activity2026-08-19+12.6%via Yahoo Finance
Merck surged +12.35% to $151.87 after announcing positive Phase 3 trial results for its personalized mRNA melanoma vaccine (INTerpath-001) developed with Moderna, per web sources. The trial met primary endpoints for recurrence-free and distant metastasis-free survival. Volume spiked to 23.6M shares, 3.68x the time-adjusted average, signaling broad institutional participation.
Valuation2026-08-12+1.9%via 247wallst.com
Merck rose 2.07% to $133.12 as Wall Street analysts repositioned ahead of Wednesday morning's CPI release and geopolitical developments in the Strait of Hormuz, according to 247wallst.com. The move comes within a broader pharma sector adjustment tied to macro catalysts rather than company-specific news. Volume of 2.84M shares ran 1.08x normal for this time of day.
Upcoming catalysts & outlook
Next earnings
2026-10-29 (est.)
in 45 days
10-Q Filing (est.)
2026-11-06
Medium impact
Thesis shift
Neutral / Mixed
bearish signal
Risk level
High
from change events

Frequently asked questions about MRK

Why did Merck & Co., Inc. (MRK) stock move?

MRK fell 0.5% to $143.94. No single company-specific catalyst was confirmed during the move window, and it looks like a sector-wide move.

How much did MRK stock fall?

MRK lost 0.54% ($0.78) versus the prior close of $144.71, last trading at $143.94 on 0.8× average volume.

When is Merck & Co., Inc.'s next earnings date?

MRK's next earnings report is estimated for 2026-10-29 — about 45 days away.

What is the analyst price target for MRK?

The consensus analyst price target for MRK is $158.12, about 9.9% above the current $143.94. Over the past 90 days, analysts recorded 2 upgrades, 21 maintains, and 1 downgrade.

Is the MRK move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median -0.3% against MRK's -0.5%. MRK ranks top 4 of 7 peers.

How BestStocks tracks MRK

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRK-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 14, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.